Viscosity of Fibre Predicts Cholesterol-lowering in Healthy Individuals

Healthy Clinical Trial

Official title:

Viscosity Rather Than Quality of Dietary Fibre Predicts Cholesterol-lowering Effect in Healthy Individuals

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03741621
• Other study ID #: viscosity and cholesterol
• Status: Completed
• Phase: Phase 2
• Start date: January 1992
• Est. completion date: July 2010

Study information

• Verified date: November 2018
• Source: St. Michael's Hospital, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate the role of fibre viscosity (low, medium, high) in lowering cholesterol in healthy individuals

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: July 2010
• Est. primary completion date: January 1994
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

-healthy individuals

Exclusion Criteria:

• regular alcohol consumption

• regular smoking

Related Conditions & MeSH terms

• Healthy
• Hyperlipidemias
• Lipidemia

Intervention

Dietary Supplement:
• Viscous Fibre Blend
High viscosity viscous fiber blend sprinkled on wheat and maize bran cereals(Bran Buds®; Kellogg Company)
• Psyllium
Bran Buds cereal (white bran and maize bran) with psyllium (Bran Buds® with PSY; Kellogg Company)
• Wheat Bran
All Bran cereal (All Bran®; Kellogg Company)

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
St. Michael's Hospital, Toronto	Kellogg Company, University of Toronto

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in LDL cholesterol		change from baseline after 21 days, relative to control
Secondary	change in total cholesterol		change from baseline after 21 days, relative to control
Secondary	change in triglycerides		change from baseline after 21 days, relative to control
Secondary	change in HDL cholesterol		change from baseline after 21 days, relative to control
Secondary	change in apolipoprotein B		change from baseline after 21 days, relative to control
Secondary	change in apolipoprotein A-1		change from baseline after 21 days, relative to control